cancer

IV vitamin C achieves clinical success with prostate and breast cancer

Wednesday, September 19, 2012 by: Ethan Evers
Tags: vitamin C, prostate cancer, breast cancer

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
White House admits staging fake vaccination operation to gather DNA from the public
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
Delicious
(NaturalNews) IV (intravenous) vitamin C therapy has already been clinically proven to markedly improve quality of life for cancer patients, but a new landmark study has shown for the first time it can reduce inflammation and tumor markers in prostate cancer and breast cancer patients. The science behind IV vitamin C as a cancer therapy is now advancing faster than ever before, with six clinical trials currently underway worldwide, including colorectal, prostate, pancreatic and other cancers.

Dual role of IV vitamin C for cancer - Cytotoxicity and inflammation

In lab studies, high-dose vitamin C has proven to be potently cytotoxic to a wide variety of cancer cell lines as well as to boost the cytotoxicity of several common chemotherapy drugs. This has been confirmed in animal studies, where IV vitamin C decreases the growth rates of liver, ovarian, pancreatic, and glioblastoma tumors with dosages easily achievable in humans. But beyond directly poisoning cancer cells, there is another role for vitamin C to play in treating cancer: the reduction of inflammation.

Recent research has shown that greater inflammation in cancer patients is associated with poor prognosis. This may be because key features of the inflammatory environment (infiltrating leucocytes, pro-inflammatory cytokine build-up, tissue remodeling and angiogenesis) may actually facilitate cancer development. With this in mind, one of the leading alternative medicine clinics in the USA designed a trial to test the ability of IV vitamin C to reduce key inflammation markers as well as tumor markers in patients with prostate, breast and other cancers. This trial included 45 patients aged 47-85, with an average age of 68. The treatments included vitamin C infusions of 25 to 50 grams, up to three times per week. The median follow-up on patients was 7.2 years (maximum of 18 years). It should be noted that most patients had already been treated by standard therapies. The total number of vitamin C infusions given to any one patient ranged from 1 up to 102.

Inflammation markers reduced in 76 percent of cancer patients

IV vitamin C therapy was successful in reducing C Reactive Protein (CRP) levels in 76 percent of all patients in the trial. This is significant, as CRP is a well-established marker for inflammation. By the end of the trial, the average patient saw a drop in CRP levels of 80 percent (for patients who started the trials with above-normal CRP levels). In addition, for a more detailed picture, serum levels of pro-inflammatory cytokines were measured for 11 patients. Of these 11 patients, all saw large reductions in these cytokines after their treatments.

Some important trends emerged from the trial. First, patients who had more IV vitamin C treatments tended to have a better response. Second, patients who began the therapy at an earlier stage of their disease had better response compared to those with more aggressive, metastatic cancer. Finally, and perhaps most importantly, patients who saw reductions in inflammation markers usually also saw reductions in tumor markers - especially for breast and prostate cancer.

Tumor markers decreased for most prostate cancer and breast cancer patients

Most impressive with this trial was that PSA levels decreased in 77 percent of prostate cancer patients while 73 percent of breast cancer patients saw decreases in CA27.29/CA15.3 (cancer antigen) and/or CEA (carcinoembryonic antigen) after their treatments.

This trial gives powerful new evidence of the benefits of IV vitamin C therapy for cancer - a therapy which has few side-effects, a well-established safety profile and which is far cheaper than conventional treatments. For more information, the last reference below links to the clinic where this trial was carried out.

Sources for this article include:

http://www.ncbi.nlm.nih.gov/pubmed/22963460
http://www.ncbi.nlm.nih.gov/pubmed/17297243
http://www.ncbi.nlm.nih.gov/pubmed/22021693
http://www.clinicaltrials.gov
http://www.ncbi.nlm.nih.gov/pubmed/18678913
http://www.ncbi.nlm.nih.gov/pubmed/19246295
http://www.naturalnews.com/034663_IV_vitamin_c_cancer_treatment.html
http://www.riordanclinic.org/

About the author:
Ethan Evers is author of the award-winning medical thriller "The Eden Prescription," in which cutting-edge researchers perfect an effective, all-natural treatment for cancer, only to be hunted down by pharmaceutical interests which will stop at nothing to protect their $80 billion cancer drug cash machine. The Eden Prescription is based on the latest science and draws on real historical events stretching back to the beginning of the "War on Cancer." Ethan has a PhD in Applied Science.

The Eden Prescription is available on amazon: www.amazon.com/Eden-Prescription-cancer-what...
Follow Ethan on Facebook for the latest breakthroughs and news on natural medicine for cancer: www.facebook.com/pages/The-Eden-Prescription...
For more information: www.edenprescription.com




Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.